Keep Canada Competitive
The Senate Standing Committee on
Social Affairs, Science and Technology, chaired by the Honourable Senator Ogilvie has been examining prescription pharmaceuticals in Canada.
Senate Committee Study on Prescription Pharmaceuticals
This study is studying the following:
- the process to approve prescription pharmaceuticals with a particular focus on clinical trials;
- the post-approval monitoring of prescription pharmaceuticals;
- the off-label use of prescription pharmaceuticals; and
- the nature of unintended consequences in the use of prescription pharmaceuticals.
BIOTECanada has been participating in the committee appearances by showcasing the leadership of our members in this area.
In April, we discusses clinical trials - read the remarks here.
In October, we discussed post approval monitoring
Andrew Casey's remarks
Loretta Del Bosco's remarks
Bio-Economy Roundtable 2012
Innovative Biotechnology Leaders Welcome The Federal Budget Announcements For New Investments
OTTAWA, ON Canada’s biotech industry was pleased to see the proposed $400 million to support creation of new large scale VC funds, $100 million for the Business Development Bank of Canada for VC activities, and the Industrial Research Assistance Program being doubled to $110 annually. Creating these incentives will facilitate investment into Canada’s emerging biotech industry. Read the news release here.
Industry Financing - Pre-budget 2012 consultations
Download the submission here.
John Hyshka, CFO Phenomenome presented to the Standing Committee on FInance. Download his remarks here.
Response to Jenkins Report
Anthony Giovinazzo, Chair of
BIOTECanada's Emerging Companies Advisory Board and Peter Brenders,
President and CEO of BIOTECanada have co-signed our response to the
Expert Panel on Research and Development. Read it here.
Together with the Canadian Manufacturers & Exporters along with others we have signed onto a letter for Minister Goodyear concerning the recommendations from the recent Expert Panel on Research and Development. Read it here.